US6143866A
(en)
*
|
1989-07-18 |
2000-11-07 |
Amgen, Inc. |
Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
|
US6552170B1
(en)
*
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US6057287A
(en)
|
1994-01-11 |
2000-05-02 |
Dyax Corp. |
Kallikrein-binding "Kunitz domain" proteins and analogues thereof
|
US20010055581A1
(en)
|
1994-03-18 |
2001-12-27 |
Lawrence Tamarkin |
Composition and method for delivery of biologically-active factors
|
US5583114A
(en)
|
1994-07-27 |
1996-12-10 |
Minnesota Mining And Manufacturing Company |
Adhesive sealant composition
|
US5672662A
(en)
*
|
1995-07-07 |
1997-09-30 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
|
KR20040010739A
(en)
|
1996-02-09 |
2004-01-31 |
암젠 인코포레이티드 |
Fusion protein comprising interleukin-1 receptor antagonist and pharmaceutical composition thereof
|
US5747639A
(en)
*
|
1996-03-06 |
1998-05-05 |
Amgen Boulder Inc. |
Use of hydrophobic interaction chromatography to purify polyethylene glycols
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
WO1998012274A1
(en)
*
|
1996-09-23 |
1998-03-26 |
Chandrashekar Pathak |
Methods and devices for preparing protein concentrates
|
US8003705B2
(en)
*
|
1996-09-23 |
2011-08-23 |
Incept Llc |
Biocompatible hydrogels made with small molecule precursors
|
DE69713517D1
(en)
|
1996-10-15 |
2002-07-25 |
Medical Analysis Systems Inc |
Process for the stabilization of troponin I (CTnI) by conjugation with an active polymer
|
AU5696198A
(en)
|
1996-12-06 |
1998-06-29 |
Amgen, Inc. |
Combination therapy using a tnf binding protein for treating tnf-mediated diseases
|
ES2615357T3
(en)
|
1996-12-06 |
2017-06-06 |
Amgen Inc. |
Combination therapy using an IL-1 inhibitor to treat IL-1 mediated diseases
|
US6743248B2
(en)
|
1996-12-18 |
2004-06-01 |
Neomend, Inc. |
Pretreatment method for enhancing tissue adhesion
|
US6371975B2
(en)
|
1998-11-06 |
2002-04-16 |
Neomend, Inc. |
Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
|
US20040176801A1
(en)
*
|
1997-03-12 |
2004-09-09 |
Neomend, Inc. |
Pretreatment method for enhancing tissue adhesion
|
US20030191496A1
(en)
*
|
1997-03-12 |
2003-10-09 |
Neomend, Inc. |
Vascular sealing device with microwave antenna
|
AU7282698A
(en)
*
|
1997-05-15 |
1998-12-08 |
Theratech, Inc. |
Targeted delivery to t lymphocytes
|
US6284246B1
(en)
|
1997-07-30 |
2001-09-04 |
The Procter & Gamble Co. |
Modified polypeptides with high activity and reduced allergenicity
|
US6251866B1
(en)
|
1997-08-05 |
2001-06-26 |
Watson Laboratories, Inc. |
Conjugates targeted to the interleukin-2 receptor
|
US6168784B1
(en)
|
1997-09-03 |
2001-01-02 |
Gryphon Sciences |
N-terminal modifications of RANTES and methods of use
|
US6129928A
(en)
*
|
1997-09-05 |
2000-10-10 |
Icet, Inc. |
Biomimetic calcium phosphate implant coatings and methods for making the same
|
US7229841B2
(en)
*
|
2001-04-30 |
2007-06-12 |
Cytimmune Sciences, Inc. |
Colloidal metal compositions and methods
|
US6407218B1
(en)
*
|
1997-11-10 |
2002-06-18 |
Cytimmune Sciences, Inc. |
Method and compositions for enhancing immune response and for the production of in vitro mabs
|
ES2307865T3
(en)
|
1998-03-12 |
2008-12-01 |
Nektar Therapeutics Al, Corporation |
METHOD FOR PREPARING POLYMERIC CONJUGATES.
|
US6066673A
(en)
*
|
1998-03-12 |
2000-05-23 |
The Procter & Gamble Company |
Enzyme inhibitors
|
US6908757B1
(en)
|
1998-03-26 |
2005-06-21 |
The Procter & Gamble Company |
Serine protease variants having amino acid deletions and substitutions
|
CN1301305A
(en)
|
1998-03-26 |
2001-06-27 |
宝洁公司 |
Serine protease variants having amino acid substitutions
|
US6495136B1
(en)
|
1998-03-26 |
2002-12-17 |
The Procter & Gamble Company |
Proteases having modified amino acid sequences conjugated to addition moieties
|
US6632457B1
(en)
*
|
1998-08-14 |
2003-10-14 |
Incept Llc |
Composite hydrogel drug delivery systems
|
US6458147B1
(en)
|
1998-11-06 |
2002-10-01 |
Neomend, Inc. |
Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
|
US6994686B2
(en)
*
|
1998-08-26 |
2006-02-07 |
Neomend, Inc. |
Systems for applying cross-linked mechanical barriers
|
CN1330675A
(en)
|
1998-08-28 |
2002-01-09 |
格莱风科学公司 |
Polyamide chains of precise length, methods to manufacture them and their conjugates with protein
|
US6551613B1
(en)
*
|
1998-09-08 |
2003-04-22 |
Alza Corporation |
Dosage form comprising therapeutic formulation
|
AU743363B2
(en)
|
1998-09-22 |
2002-01-24 |
Procter & Gamble Company, The |
Personal care compositions containing active proteins tethered to a water insoluble substrate
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US7279001B2
(en)
*
|
1998-11-06 |
2007-10-09 |
Neomend, Inc. |
Systems, methods, and compositions for achieving closure of vascular puncture sites
|
US6899889B1
(en)
*
|
1998-11-06 |
2005-05-31 |
Neomend, Inc. |
Biocompatible material composition adaptable to diverse therapeutic indications
|
US6949114B2
(en)
|
1998-11-06 |
2005-09-27 |
Neomend, Inc. |
Systems, methods, and compositions for achieving closure of vascular puncture sites
|
US6830756B2
(en)
*
|
1998-11-06 |
2004-12-14 |
Neomend, Inc. |
Systems, methods, and compositions for achieving closure of vascular puncture sites
|
WO2000033764A1
(en)
|
1998-12-04 |
2000-06-15 |
Pathak Chandrashekhar P |
Biocompatible crosslinked polymers
|
US6958212B1
(en)
*
|
1999-02-01 |
2005-10-25 |
Eidgenossische Technische Hochschule Zurich |
Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
|
CA2359318C
(en)
|
1999-02-01 |
2009-06-30 |
Donald Elbert |
Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
|
WO2000078285A1
(en)
*
|
1999-06-18 |
2000-12-28 |
University Of Medicine And Dentistry Of New Jersey |
Controlled release of therapeutics by in-situ entrapment by matrix cross-linking
|
MXPA02000842A
(en)
|
1999-07-22 |
2002-07-30 |
Procter & Gamble |
Protease conjugates having sterically protected clip sites.
|
CZ2002220A3
(en)
|
1999-07-22 |
2002-05-15 |
The Procter & Gamble Company |
Subtilisin protease variants with deletions and substitution of amino acids in defined epitope regions
|
US6946128B1
(en)
|
1999-07-22 |
2005-09-20 |
The Procter & Gamble Company |
Protease conjugates having sterically protected epitope regions
|
CZ2002212A3
(en)
|
1999-07-22 |
2002-07-17 |
The Procter & Gamble Company |
Variants of subtilisin protease having amino acid substitutions in defined epitope regions
|
US7008635B1
(en)
|
1999-09-10 |
2006-03-07 |
Genzyme Corporation |
Hydrogels for orthopedic repair
|
US6303119B1
(en)
|
1999-09-22 |
2001-10-16 |
The Procter & Gamble Company |
Personal care compositions containing subtilisin enzymes bound to water insoluble substrates
|
US7074878B1
(en)
*
|
1999-12-10 |
2006-07-11 |
Harris J Milton |
Hydrolytically degradable polymers and hydrogels made therefrom
|
US6348558B1
(en)
|
1999-12-10 |
2002-02-19 |
Shearwater Corporation |
Hydrolytically degradable polymers and hydrogels made therefrom
|
ES2327606T3
(en)
|
2000-01-10 |
2009-11-02 |
Maxygen Holdings Ltd |
CONJUGATES OF G-CSF.
|
DE60138364D1
(en)
|
2000-02-11 |
2009-05-28 |
Bayer Healthcare Llc |
CLEANING FACTOR VII OR VIIA CONJUGATE
|
EP1284818B1
(en)
|
2000-05-15 |
2006-11-22 |
Tecan Trading AG |
Bidirectional flow centrifugal microfluidic devices
|
NZ522847A
(en)
*
|
2000-05-16 |
2004-11-26 |
Bolder Biotechnology Inc |
Methods for refolding proteins containing free cysteine residues
|
US7291673B2
(en)
*
|
2000-06-02 |
2007-11-06 |
Eidgenossiche Technische Hochschule Zurich |
Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
|
KR20030032977A
(en)
*
|
2000-07-12 |
2003-04-26 |
그리폰 테라퓨틱스, 인코포레이티드 |
Chemokine receptor modulators, production and use
|
US7118737B2
(en)
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
RU2003109746A
(en)
*
|
2000-09-08 |
2005-01-27 |
Грифон Терапьютикс, Инк. (Us) |
SYNTHETIC PROTEINS STIMULATING ERYTHROPOESIS
|
JP4070605B2
(en)
*
|
2000-10-19 |
2008-04-02 |
アイトゲノッシスシェ・テヒニッシュ・ホーホシューレ・ツューリヒ |
Block copolymers for multifunctional self-assembled systems
|
CN1507357A
(en)
|
2000-10-31 |
2004-06-23 |
PRҩƷ����˾ |
Method and compositions for enhanced delivery of bioactive molecules
|
TW593427B
(en)
*
|
2000-12-18 |
2004-06-21 |
Nektar Therapeutics Al Corp |
Synthesis of high molecular weight non-peptidic polymer derivatives
|
US7053150B2
(en)
*
|
2000-12-18 |
2006-05-30 |
Nektar Therapeutics Al, Corporation |
Segmented polymers and their conjugates
|
YU48703A
(en)
|
2001-02-27 |
2006-05-25 |
Maxygen Aps |
New interferon beta-like molecules
|
MXPA03008498A
(en)
*
|
2001-03-20 |
2005-06-30 |
Univ Zuerich |
Two-phase processing of thermosensitive polymers for use as biomaterials.
|
US6538104B2
(en)
|
2001-04-27 |
2003-03-25 |
Medical Analysis Systems, Inc. |
Stabilization of cardiac troponin I subunits and complexes
|
US20040077835A1
(en)
*
|
2001-07-12 |
2004-04-22 |
Robin Offord |
Chemokine receptor modulators, production and use
|
WO2003018665A1
(en)
*
|
2001-08-22 |
2003-03-06 |
Bioartificial Gel Technologies Inc. |
Process for the preparation of activated polyethylene glycols
|
NZ532027A
(en)
|
2001-10-10 |
2008-09-26 |
Neose Technologies Inc |
Remodeling and glycoconjugation of peptides
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US8008252B2
(en)
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
CN105131104B
(en)
|
2001-10-10 |
2018-11-16 |
诺和诺德公司 |
The reconstruct and sugar conjugation of peptide
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
EP2939696B1
(en)
|
2001-10-18 |
2016-03-09 |
Nektar Therapeutics |
Polymer conjugates of opioid antagonists
|
JP2005509444A
(en)
*
|
2001-11-23 |
2005-04-14 |
シモン・フレデリックソン |
Methods and kits for proximity probing with multivalent proximity probes
|
EA009783B1
(en)
|
2002-01-18 |
2008-04-28 |
Байоджен Айдек Ма Инк. |
Polyalkylene glycolhaving a moiety for conjugation of a biologically active compound
|
US20030179692A1
(en)
*
|
2002-03-19 |
2003-09-25 |
Yoshitaka Ohotomo |
Storage medium
|
US8282912B2
(en)
*
|
2002-03-22 |
2012-10-09 |
Kuros Biosurgery, AG |
Compositions for tissue augmentation
|
JP2005534647A
(en)
|
2002-06-07 |
2005-11-17 |
ダイアックス、コープ |
Prevention and reduction of blood loss
|
US7153829B2
(en)
|
2002-06-07 |
2006-12-26 |
Dyax Corp. |
Kallikrein-inhibitor therapies
|
DK1517710T3
(en)
|
2002-06-21 |
2011-07-18 |
Novo Nordisk Healthcare Ag |
Pegylated factor VII glycoforms
|
DE60336555D1
(en)
|
2002-06-21 |
2011-05-12 |
Novo Nordisk Healthcare Ag |
PEGYLATED GLYCO FORMS OF FACTOR VII
|
US7034127B2
(en)
*
|
2002-07-02 |
2006-04-25 |
Genzyme Corporation |
Hydrophilic biopolymer-drug conjugates, their preparation and use
|
CA2497777A1
(en)
*
|
2002-09-05 |
2004-03-18 |
The General Hospital Corporation |
Modified asialo-interferons and uses thereof
|
AU2003268463A1
(en)
*
|
2002-09-05 |
2004-03-29 |
The General Hospital Corporation |
Asialo-interferons and the treatment of liver cancer
|
ES2315526T3
(en)
|
2002-09-09 |
2009-04-01 |
Nektar Therapeutics Al, Corporation |
METHOD FOR PREPARING WATER SOLUBLE POLYMER DERIVATIVES THAT CARRY A TERMINAL CARBOXYLIC ACID.
|
CN1312279C
(en)
*
|
2002-11-07 |
2007-04-25 |
连云港新阳医药有限公司 |
Method for preparing elspar modilfied by carbowax
|
PL219741B1
(en)
*
|
2002-12-26 |
2015-07-31 |
Mountain View Pharmaceuticals |
Polymer conjugates of interferon-beta with enhanced biological potency
|
TWI364295B
(en)
*
|
2002-12-26 |
2012-05-21 |
Mountain View Pharmaceuticals |
Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
WO2004061094A1
(en)
|
2002-12-30 |
2004-07-22 |
Gryphon Therapeutics, Inc. |
Water-soluble thioester and selenoester compounds and methods for making and using the same
|
US20060014248A1
(en)
*
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
US20050130892A1
(en)
*
|
2003-03-07 |
2005-06-16 |
Xencor, Inc. |
BAFF variants and methods thereof
|
DE602004029646D1
(en)
|
2003-01-06 |
2010-12-02 |
Nektar Therapeutics San Carlos |
Thiolselektive wasserlösliche polymerderivate
|
US20050221443A1
(en)
*
|
2003-01-06 |
2005-10-06 |
Xencor, Inc. |
Tumor necrosis factor super family agonists
|
CN1723232B
(en)
*
|
2003-01-06 |
2012-08-22 |
尼克塔治疗公司 |
Thiol-selective water-soluble polmer derivatives
|
US7553930B2
(en)
*
|
2003-01-06 |
2009-06-30 |
Xencor, Inc. |
BAFF variants and methods thereof
|
SI1596887T1
(en)
*
|
2003-02-26 |
2022-05-31 |
Nektar Therapeutics |
Polymer-factor viii moiety conjugates
|
CA2517145C
(en)
*
|
2003-03-05 |
2017-08-01 |
Halozyme, Inc. |
Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
KR20060003862A
(en)
|
2003-03-14 |
2006-01-11 |
네오스 테크놀로지스, 인크. |
Branched water-soluble polymers and their eonjugates
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
AU2004227937B2
(en)
*
|
2003-03-31 |
2007-09-20 |
Xencor, Inc |
Methods for rational pegylation of proteins
|
US7610156B2
(en)
*
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
US20070026485A1
(en)
|
2003-04-09 |
2007-02-01 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
WO2006127896A2
(en)
*
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Glycopegylated factor ix
|
AU2004229461A1
(en)
|
2003-04-11 |
2004-10-28 |
Pr Pharmaceuticals Inc. |
Method for preparation of site-specific protein conjugates
|
WO2004091517A2
(en)
|
2003-04-15 |
2004-10-28 |
Smithkline Beecham Corporation |
Conjugates comprising human il-18 and substitution mutants thereof
|
US7932364B2
(en)
|
2003-05-09 |
2011-04-26 |
Novo Nordisk A/S |
Compositions and methods for the preparation of human growth hormone glycosylation mutants
|
US20040249119A1
(en)
*
|
2003-06-05 |
2004-12-09 |
Fox Martin Edward |
Novel mPEG propionaldehyde precursor
|
GB0316294D0
(en)
|
2003-07-11 |
2003-08-13 |
Polytherics Ltd |
Conjugated biological molecules and their preparation
|
EP1656410B1
(en)
|
2003-07-22 |
2010-03-10 |
Nektar Therapeutics |
Method for preparing functionalized polymers from polymer alcohols
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
CA2536873C
(en)
*
|
2003-08-29 |
2019-09-10 |
Dyax Corp. |
Poly-pegylated protease inhibitors
|
PL1675622T3
(en)
|
2003-09-17 |
2017-11-30 |
Nektar Therapeutics |
Multi-arm polymer prodrugs
|
SG143252A1
(en)
*
|
2003-10-09 |
2008-06-27 |
Ambrx Inc |
Polymer derivatives
|
US7524813B2
(en)
*
|
2003-10-10 |
2009-04-28 |
Novo Nordisk Health Care Ag |
Selectively conjugated peptides and methods of making the same
|
CN102516386A
(en)
|
2003-10-10 |
2012-06-27 |
诺沃挪第克公司 |
Il-21 derivatives
|
EP1675871A2
(en)
|
2003-10-10 |
2006-07-05 |
Xencor Inc. |
Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
|
EP2641611A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
EP1725572B1
(en)
|
2003-11-05 |
2017-05-31 |
AGCT GmbH |
Macromolecular nucleotide compounds and methods for using the same
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
EP1694347B1
(en)
*
|
2003-11-24 |
2013-11-20 |
BioGeneriX AG |
Glycopegylated erythropoietin
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
EP1694301A4
(en)
|
2003-12-02 |
2009-11-18 |
Cytimmune Sciences Inc |
Methods and compositions for the production of monoclonal antibodies
|
US7956032B2
(en)
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
US20060040856A1
(en)
*
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
KR101439880B1
(en)
*
|
2004-01-08 |
2014-09-12 |
라티오팜 게엠베하 |
O-linked glycosylation of peptides
|
JP4833862B2
(en)
*
|
2004-01-28 |
2011-12-07 |
サイトイミューン サイエンシズ インコーポレイテッド |
Functionalized colloidal metal compositions and methods
|
AU2005211362B2
(en)
|
2004-02-02 |
2008-03-13 |
Ambrx, Inc. |
Modified human interferon polypeptides and their uses
|
AU2005319099B2
(en)
*
|
2004-02-02 |
2010-09-16 |
Ambrx, Inc. |
Modified human growth hormone
|
KR100580644B1
(en)
*
|
2004-02-16 |
2006-05-16 |
삼성전자주식회사 |
A method for noncovalently immobilizing a biomolecule on a solid substrate and a microarray produced by the same
|
US7351787B2
(en)
*
|
2004-03-05 |
2008-04-01 |
Bioartificial Gel Technologies, Inc. |
Process for the preparation of activated polyethylene glycols
|
CN101132812A
(en)
*
|
2004-03-15 |
2008-02-27 |
阿拉巴马耐科塔医药公司 |
Polymer-based compositions and conjuates of HIV entry inhibitors
|
US20070265200A1
(en)
*
|
2004-03-17 |
2007-11-15 |
Eli Lilly And Company |
Glycol Linked Fgf-21 Compounds
|
WO2005115477A2
(en)
|
2004-04-13 |
2005-12-08 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
CA2568952C
(en)
*
|
2004-06-18 |
2019-05-21 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
EP1771066A2
(en)
|
2004-07-13 |
2007-04-11 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
|
AU2005275062A1
(en)
|
2004-07-14 |
2006-02-23 |
University Of Utah Research Foundation |
Netrin-related compositions and uses
|
MX2007000728A
(en)
*
|
2004-07-21 |
2007-03-15 |
Ambrx Inc |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids.
|
US8268967B2
(en)
|
2004-09-10 |
2012-09-18 |
Novo Nordisk A/S |
Glycopegylated interferon α
|
US20060204512A1
(en)
|
2004-09-23 |
2006-09-14 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
US7235530B2
(en)
|
2004-09-27 |
2007-06-26 |
Dyax Corporation |
Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
|
JP4920593B2
(en)
*
|
2004-10-25 |
2012-04-18 |
インテザイン テクノロジーズ, インコーポレイテッド |
Heterobifunctional poly (ethylene glycol) and their use
|
ES2572779T3
(en)
|
2004-10-29 |
2016-06-02 |
Ratiopharm Gmbh |
Remodeling and glucopegilation of Fibroblast Growth Factor (FGF)
|
US7851565B2
(en)
|
2004-12-21 |
2010-12-14 |
Nektar Therapeutics |
Stabilized polymeric thiol reagents
|
NZ555386A
(en)
*
|
2004-12-22 |
2011-01-28 |
Ambrx Inc |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
EP1836316A4
(en)
|
2004-12-22 |
2009-07-22 |
Ambrx Inc |
Methods for expression and purification of recombinant human growth hormone
|
JP5425398B2
(en)
|
2004-12-22 |
2014-02-26 |
アンブレツクス・インコーポレイテツド |
Compositions comprising unnatural amino acids and polypeptides, methods relating to unnatural amino acids and polypeptides, and uses of unnatural amino acids and polypeptides
|
JP4990792B2
(en)
*
|
2004-12-22 |
2012-08-01 |
アンブレツクス・インコーポレイテツド |
Compositions of aminoacyl-tRNA synthetases and uses thereof
|
ES2449195T3
(en)
|
2005-01-10 |
2014-03-18 |
Ratiopharm Gmbh |
Glycopegylated granulocyte colony stimulating factor
|
US7402730B1
(en)
|
2005-02-03 |
2008-07-22 |
Lexicon Pharmaceuticals, Inc. |
Knockout animals manifesting hyperlipidemia
|
AU2006213822B2
(en)
*
|
2005-02-09 |
2011-05-26 |
Covidien Lp |
Synthetic sealants
|
JP2008534640A
(en)
|
2005-04-05 |
2008-08-28 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
Method for shielding functional site or epitope of protein
|
EP2386571B1
(en)
|
2005-04-08 |
2016-06-01 |
ratiopharm GmbH |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
WO2006110776A2
(en)
|
2005-04-12 |
2006-10-19 |
Nektar Therapeutics Al, Corporation |
Polyethylene glycol cojugates of antimicrobial agents
|
RU2412199C2
(en)
|
2005-04-18 |
2011-02-20 |
Ново Нордиск А/С |
Versions of il-21
|
US7833979B2
(en)
*
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
PT1881850E
(en)
|
2005-05-13 |
2010-11-26 |
Lilly Co Eli |
Glp-1 pegylated compounds
|
EP1888098A2
(en)
|
2005-05-25 |
2008-02-20 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin formulations
|
US9505867B2
(en)
*
|
2005-05-31 |
2016-11-29 |
Ecole Polytechmique Fédérale De Lausanne |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
ATE529442T1
(en)
*
|
2005-06-03 |
2011-11-15 |
Ambrx Inc |
IMPROVED HUMAN INTERFERON MOLECULES AND THEIR USES
|
US20060281712A1
(en)
|
2005-06-14 |
2006-12-14 |
Chi-Feng Yen |
Pyrimidine compounds
|
US8193206B2
(en)
|
2005-06-14 |
2012-06-05 |
Taigen Biotechnology Co., Ltd. |
Pyrimidine compounds
|
JP5335422B2
(en)
|
2005-06-17 |
2013-11-06 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Selective reduction and derivatization of engineered proteins containing at least one unnatural cysteine
|
EP2412744B1
(en)
|
2005-07-18 |
2014-01-22 |
Nektar Therapeutics |
Method for preparing branched functionalised polymers using branched polyol cores
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
CN103103238B
(en)
*
|
2005-08-18 |
2016-08-10 |
Ambrx公司 |
A kind of manufacture in cell has selected amino acid whose antibody or the method for antibody fragment polypeptide in specific location
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
AU2006311568B2
(en)
*
|
2005-11-08 |
2010-11-11 |
Ambrx, Inc. |
Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
|
EP1951890A4
(en)
*
|
2005-11-16 |
2009-06-24 |
Ambrx Inc |
Methods and compositions comprising non-natural amino acids
|
DK1968635T3
(en)
*
|
2005-12-14 |
2014-12-15 |
Ambrx Inc |
Compositions and Methods of, and uses of non-natural amino acids and polypeptides
|
US8293869B2
(en)
*
|
2005-12-16 |
2012-10-23 |
Nektar Therapeutics |
Polymer conjugates of GLP-1
|
US7743730B2
(en)
*
|
2005-12-21 |
2010-06-29 |
Lam Research Corporation |
Apparatus for an optimized plasma chamber grounded electrode assembly
|
EP1981525B1
(en)
*
|
2005-12-30 |
2015-01-21 |
Zensun (Shanghai) Science and Technology Limited |
Extended release of neuregulin for improved cardiac function
|
RU2427383C2
(en)
*
|
2006-01-18 |
2011-08-27 |
КьюПиЭс, ЭлЭлСи |
High stability pharmaceutical compositions
|
EP2319542B1
(en)
|
2006-02-21 |
2018-03-21 |
Nektar Therapeutics |
Segmented degradable polymers and conjugates made therefrom
|
EP2004231A4
(en)
|
2006-04-07 |
2013-07-10 |
Nektar Therapeutics |
Conjugates of an anti-tnf-alpha antibody
|
EP2573111A1
(en)
|
2006-04-20 |
2013-03-27 |
Amgen Inc. |
GLP-1 compounds
|
CA2861601A1
(en)
*
|
2006-04-27 |
2007-11-08 |
Intezyne Technologies, Inc. |
Poly (ethylene glycol) containing chemically disparate endgroups
|
EP2213733A3
(en)
|
2006-05-24 |
2010-12-29 |
Novo Nordisk Health Care AG |
Factor IX analogues having prolonged in vivo half life
|
US8242179B2
(en)
*
|
2006-06-23 |
2012-08-14 |
Surmodics, Inc. |
Hydrogel-based joint repair system and method
|
WO2007149594A2
(en)
|
2006-06-23 |
2007-12-27 |
Quintessence Biosciences, Inc. |
Modified ribonucleases
|
US8298801B2
(en)
*
|
2006-07-17 |
2012-10-30 |
Quintessence Biosciences, Inc. |
Methods and compositions for the treatment of cancer
|
US9187532B2
(en)
|
2006-07-21 |
2015-11-17 |
Novo Nordisk A/S |
Glycosylation of peptides via O-linked glycosylation sequences
|
EP2615108B1
(en)
*
|
2006-09-08 |
2016-10-26 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and thier uses
|
DK2061878T3
(en)
*
|
2006-09-08 |
2014-04-07 |
Ambrx Inc |
HYBRID SUPPRESSOR TRNA FOR ANIMAL CELLS
|
MX2009002526A
(en)
*
|
2006-09-08 |
2009-04-16 |
Ambrx Inc |
Suppressor trna transcription in vertebrate cells.
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
EP2054521A4
(en)
|
2006-10-03 |
2012-12-19 |
Novo Nordisk As |
Methods for the purification of polypeptide conjugates
|
JP5457185B2
(en)
*
|
2006-10-04 |
2014-04-02 |
ノヴォ ノルディスク アー/エス |
Glycerol-linked PEGylated sugars and glycopeptides
|
PE20081140A1
(en)
*
|
2006-10-25 |
2008-09-22 |
Amgen Inc |
THERAPEUTIC AGENTS BASED ON PEPTIDES DERIVED FROM TOXINS
|
CN101553501A
(en)
|
2006-10-26 |
2009-10-07 |
诺沃-诺迪斯克有限公司 |
IL-21 variants
|
AU2007325838B2
(en)
|
2006-11-22 |
2013-09-19 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
CN101583380B
(en)
*
|
2006-11-30 |
2013-07-10 |
尼克塔治疗公司 |
Method for preparing a polymer conjugate
|
PT2121751T
(en)
|
2006-12-08 |
2017-04-18 |
Lexicon Pharmaceuticals Inc |
Monoclonal antibodies against angptl3
|
WO2008076933A2
(en)
|
2006-12-14 |
2008-06-26 |
Bolder Biotechnology, Inc. |
Long acting proteins and peptides and methods of making and using the same
|
WO2008075192A2
(en)
*
|
2006-12-19 |
2008-06-26 |
Bracco International Bv |
Targeting and therapeutic compounds and gas-filled microvesicles comprising said com ounds
|
JP5340956B2
(en)
|
2006-12-20 |
2013-11-13 |
アーケマ・インコーポレイテッド |
Encapsulation and / or binding of polymers
|
PT2842967T
(en)
|
2007-01-18 |
2017-01-13 |
Lilly Co Eli |
Pegylated amyloid beta fab
|
AU2008210434C8
(en)
|
2007-01-31 |
2014-03-27 |
Dana-Farber Cancer Institute, Inc. |
Stabilized p53 peptides and uses thereof
|
US20100144599A1
(en)
|
2007-02-02 |
2010-06-10 |
Bristol-Myers Squibb Company |
Vegf pathway blockade
|
US20090227689A1
(en)
*
|
2007-03-05 |
2009-09-10 |
Bennett Steven L |
Low-Swelling Biocompatible Hydrogels
|
US20090227981A1
(en)
*
|
2007-03-05 |
2009-09-10 |
Bennett Steven L |
Low-Swelling Biocompatible Hydrogels
|
ATE554785T1
(en)
|
2007-03-30 |
2012-05-15 |
Ambrx Inc |
MODIFIED FGF-21 POLYPEPTIDES AND THEIR USE
|
CA2682897C
(en)
|
2007-04-03 |
2016-11-22 |
Biogenerix Ag |
Methods of treatment using glycopegylated g-csf
|
PL2136850T3
(en)
*
|
2007-04-13 |
2012-07-31 |
Kuros Biosurgery Ag |
Polymeric tissue sealant
|
WO2008137471A2
(en)
*
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
MX2009012609A
(en)
|
2007-05-22 |
2009-12-07 |
Amgen Inc |
Compositions and methods for producing bioactive fusion proteins.
|
CN101778859B
(en)
|
2007-06-12 |
2014-03-26 |
诺和诺德公司 |
Improved process for the production of nucleotide sugars
|
US7968811B2
(en)
*
|
2007-06-29 |
2011-06-28 |
Harley-Davidson Motor Company Group, Inc. |
Integrated ignition and key switch
|
US9125807B2
(en)
*
|
2007-07-09 |
2015-09-08 |
Incept Llc |
Adhesive hydrogels for ophthalmic drug delivery
|
CN101361968B
(en)
|
2007-08-06 |
2011-08-03 |
健能隆医药技术(上海)有限公司 |
Use of interleukin-22 in treating fatty liver
|
CA2695991A1
(en)
*
|
2007-08-09 |
2009-02-12 |
Daiichi Sankyo Company, Limited |
Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
|
US8067028B2
(en)
*
|
2007-08-13 |
2011-11-29 |
Confluent Surgical Inc. |
Drug delivery device
|
US20090075887A1
(en)
*
|
2007-08-21 |
2009-03-19 |
Genzyme Corporation |
Treatment with Kallikrein Inhibitors
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
US20110014118A1
(en)
*
|
2007-09-21 |
2011-01-20 |
Lawrence Tamarkin |
Nanotherapeutic colloidal metal compositions and methods
|
EP2200932A4
(en)
*
|
2007-09-21 |
2014-09-10 |
Cytimmune Sciences Inc |
Nanotherapeutic colloidal metal compositions and methods
|
EP2205271B1
(en)
*
|
2007-10-08 |
2014-05-21 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapies
|
EP2214716B1
(en)
|
2007-10-23 |
2021-11-17 |
Nektar Therapeutics |
Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
|
WO2009062151A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Cytimmune Sciences, Inc. |
Compositions and methods for generating antibodies
|
US20090123519A1
(en)
*
|
2007-11-12 |
2009-05-14 |
Surmodics, Inc. |
Swellable hydrogel matrix and methods
|
JP2011504463A
(en)
*
|
2007-11-12 |
2011-02-10 |
イントラダイム コーポレイション |
Heterobifunctional polyethylene glycol reagent
|
EP2930182A1
(en)
|
2007-11-20 |
2015-10-14 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
SG188143A1
(en)
|
2008-02-08 |
2013-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
US20130189239A1
(en)
|
2008-02-27 |
2013-07-25 |
Novo Nordisk A/S |
Conjugated Factor VIII Molecules
|
TWI395593B
(en)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
In vivo temporal control of activatable matrix-degrading enzymes
|
US20090226531A1
(en)
*
|
2008-03-07 |
2009-09-10 |
Allergan, Inc. |
Methods and composition for intraocular delivery of therapeutic sirna
|
SG187427A1
(en)
|
2008-04-14 |
2013-02-28 |
Halozyme Inc |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
AU2008355098B2
(en)
|
2008-04-21 |
2012-11-15 |
Gpcr Therapeutics, Inc |
Heterocyclic compounds
|
TWI394580B
(en)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
Super fast-acting insulin compositions
|
KR20110008075A
(en)
*
|
2008-05-16 |
2011-01-25 |
넥타르 테라퓨틱스 |
Conjugates of a cholinesterase moiety and a polymer
|
AR071874A1
(en)
|
2008-05-22 |
2010-07-21 |
Bristol Myers Squibb Co |
ARMAZON DOMAIN PROTEINS BASED ON MULTIVALENT FIBRONECTINE
|
ES2536882T3
(en)
*
|
2008-07-21 |
2015-05-29 |
Polytherics Limited |
New reagents and method of conjugation of biological molecules
|
US10138283B2
(en)
|
2008-07-23 |
2018-11-27 |
Ambrx, Inc. |
Modified bovine G-CSF polypeptides and their uses
|
KR101671537B1
(en)
|
2008-08-11 |
2016-11-01 |
넥타르 테라퓨틱스 |
Multi-arm polymeric alkanoate Conjugates
|
WO2010033224A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of kiss1 peptides
|
EP2334337A1
(en)
*
|
2008-09-19 |
2011-06-22 |
Nektar Therapeutics |
Polymer conjugates of opioid growth factor peptides
|
EP2344200A2
(en)
*
|
2008-09-19 |
2011-07-20 |
Nektar Therapeutics |
Modified therapeutics peptides, methods of their preparation and use
|
EP2344199A1
(en)
*
|
2008-09-19 |
2011-07-20 |
Nektar Therapeutics |
Polymer conjugates of thymosin alpha 1 peptides
|
EP2334338A2
(en)
*
|
2008-09-19 |
2011-06-22 |
Nektar Therapeutics |
Polymer conjugates of c-peptides
|
WO2010033205A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of v681-like peptides
|
US20110171164A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of glp-2-like peptides
|
WO2010033215A2
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of aod-like peptides
|
US20110171166A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of osteocalcin peptides
|
WO2010033222A2
(en)
*
|
2008-09-19 |
2010-03-25 |
Netkar Therapeutics |
Polymer conjugates of ziconotide peptides
|
US20110171161A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of protegrin peptides
|
WO2010033216A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of nesiritide peptides
|
EP2350118B1
(en)
|
2008-09-19 |
2016-03-30 |
Nektar Therapeutics |
Carbohydrate-based drug delivery polymers and conjugates thereof
|
CN102232085A
(en)
|
2008-09-26 |
2011-11-02 |
Ambrx公司 |
Modified animal erythropoietin polypeptides and their uses
|
MX2011003196A
(en)
|
2008-09-26 |
2011-04-27 |
Ambrx Inc |
Non-natural amino acid replication-dependent microorganisms and vaccines.
|
BRPI0920743A2
(en)
|
2008-10-01 |
2016-09-20 |
Quintessence Biosciences Inc |
therapeutic ribonucleases
|
WO2010056847A2
(en)
|
2008-11-13 |
2010-05-20 |
Taigen Biotechnology Co., Ltd. |
Lyophilization formulation
|
JP5814793B2
(en)
|
2008-11-25 |
2015-11-17 |
エコール ポリテクニク フェデラル ド ローザンヌ(エーペーエフエル) |
Block copolymer and use thereof
|
KR101546563B1
(en)
|
2008-12-09 |
2015-08-28 |
할로자임, 아이엔씨 |
Extended soluble ph20 polypeptides and uses thereof
|
GB0823309D0
(en)
*
|
2008-12-19 |
2009-01-28 |
Univ Bath |
Functionalising reagents and their uses
|
AU2010203712A1
(en)
*
|
2009-01-06 |
2010-07-15 |
Dyax Corp. |
Treatment of mucositis with kallikrein inhibitors
|
US20110318322A1
(en)
|
2009-01-12 |
2011-12-29 |
Nektar Therapeutics |
Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
|
EP2396070A4
(en)
|
2009-02-12 |
2012-09-19 |
Incept Llc |
Drug delivery through hydrogel plugs
|
US9005598B2
(en)
|
2009-03-04 |
2015-04-14 |
Polytherics Limited |
Conjugated proteins and peptides
|
US8067201B2
(en)
*
|
2009-04-17 |
2011-11-29 |
Bristol-Myers Squibb Company |
Methods for protein refolding
|
AU2010258752B2
(en)
|
2009-06-09 |
2015-07-09 |
Prolong Pharmaceuticals, LLC |
Hemoglobin compositions
|
IN2012DN00407A
(en)
|
2009-08-05 |
2015-08-21 |
Pieris Ag |
|
IN2012DN03219A
(en)
|
2009-09-17 |
2015-10-23 |
Baxter Healthcare Sa |
|
WO2011050938A1
(en)
|
2009-10-26 |
2011-05-05 |
Genovoxx Gmbh |
Conjugates of nucleotides and method for the application thereof
|
CA2778678A1
(en)
|
2009-10-30 |
2011-05-05 |
Cns Therapeutics, Inc. |
Improved neurturin molecules
|
MX349301B
(en)
|
2009-12-21 |
2017-07-21 |
Ambrx Inc |
Modified bovine somatotropin polypeptides and their uses.
|
BR112012015597A2
(en)
|
2009-12-21 |
2017-01-31 |
Ambrx Inc |
modified porcine somatotropin peptides and their uses
|
JO2976B1
(en)
|
2009-12-22 |
2016-03-15 |
ايلي ليلي اند كومباني |
Oxyntomodulin peptide analogue
|
AR079344A1
(en)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
|
SI2521568T1
(en)
*
|
2010-01-06 |
2019-01-31 |
Dyax Corp. |
Plasma kallikrein binding proteins
|
CN102161754B
(en)
*
|
2010-02-13 |
2012-06-13 |
华中科技大学同济医学院附属协和医院 |
Functional modification method for branched polyethylene glycol (PEG) derivative
|
US9815876B2
(en)
|
2010-03-05 |
2017-11-14 |
Omeros Corporation |
Chimeric inhibitor molecules of complement activation
|
AU2011248625B2
(en)
|
2010-04-26 |
2017-01-05 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
|
JP6294074B2
(en)
|
2010-04-27 |
2018-03-14 |
エータイアー ファーマ, インコーポレイテッド |
Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of isoleucyl-tRNA synthetase
|
WO2011139853A2
(en)
|
2010-04-28 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
|
US9068177B2
(en)
|
2010-04-29 |
2015-06-30 |
Atyr Pharma, Inc |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
|
CA2797374C
(en)
|
2010-04-29 |
2021-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
|
CA2797393C
(en)
|
2010-04-29 |
2020-03-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
|
CN103096925A
(en)
|
2010-05-03 |
2013-05-08 |
Atyr医药公司 |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-tRNA synthetases
|
CN103096912A
(en)
|
2010-05-03 |
2013-05-08 |
Atyr医药公司 |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
|
CA2797978C
(en)
|
2010-05-03 |
2019-12-03 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
|
CN102985103A
(en)
|
2010-05-04 |
2013-03-20 |
Atyr医药公司 |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
|
WO2011143274A1
(en)
|
2010-05-10 |
2011-11-17 |
Perseid Therapeutics |
Polypeptide inhibitors of vla4
|
JP6396656B2
(en)
|
2010-05-14 |
2018-09-26 |
エータイアー ファーマ, インコーポレイテッド |
Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of phenylalanyl βtRNA synthetase
|
JP6027965B2
(en)
|
2010-05-17 |
2016-11-16 |
エータイアー ファーマ, インコーポレイテッド |
Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of leucyl-tRNA synthetase
|
MX2012013375A
(en)
|
2010-05-17 |
2013-04-11 |
Cebix Inc |
Pegylated c-peptide.
|
ES2573108T3
(en)
|
2010-05-26 |
2016-06-06 |
Bristol-Myers Squibb Company |
Fibronectin-based framework proteins that have improved stability
|
US8962560B2
(en)
|
2010-06-01 |
2015-02-24 |
Atyr Pharma Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
|
CA2804416C
(en)
|
2010-07-12 |
2020-04-28 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
|
EP2595624B1
(en)
|
2010-07-20 |
2018-01-31 |
Halozyme, Inc. |
Methods of treatment or prevention of the adverse side-effects associated with administration of an anti-hyaluronan agent
|
KR102139022B1
(en)
|
2010-07-30 |
2020-07-29 |
알콘 인코포레이티드 |
A silicone hydrogel lens with a crosslinked hydrophilic coating
|
HUE045845T2
(en)
|
2010-08-17 |
2021-12-28 |
Ambrx Inc |
Modified relaxin polypeptides and their uses
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
AU2011293294B2
(en)
|
2010-08-25 |
2016-03-24 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
|
US8961501B2
(en)
|
2010-09-17 |
2015-02-24 |
Incept, Llc |
Method for applying flowable hydrogels to a cornea
|
AR083006A1
(en)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
|
WO2012054822A1
(en)
|
2010-10-22 |
2012-04-26 |
Nektar Therapeutics |
Pharmacologically active polymer-glp-1 conjugates
|
AU2011325910B2
(en)
|
2010-11-12 |
2016-03-24 |
Dana Farber Cancer Institute, Inc. |
Cancer therapies and diagnostics
|
LT2637694T
(en)
|
2010-11-12 |
2021-05-25 |
Nektar Therapeutics |
Conjugates of an il-2 moiety and a polymer
|
RU2013123793A
(en)
|
2010-11-24 |
2014-12-27 |
Лексикон Фармасьютикалз, Инк. |
ANTIBODIES RELATING TO NOTUM PECTINACETHYLESTERASE
|
US20140371258A1
(en)
|
2010-12-17 |
2014-12-18 |
Nektar Therapeutics |
Water-Soluble Polymer Conjugates of Topotecan
|
US10736969B2
(en)
|
2010-12-21 |
2020-08-11 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
|
US20130331443A1
(en)
|
2010-12-22 |
2013-12-12 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of taxane-based compounds
|
US10894087B2
(en)
|
2010-12-22 |
2021-01-19 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
CN103635489B
(en)
|
2011-01-06 |
2016-04-13 |
戴埃克斯有限公司 |
Blood plasma prekallikrein associated proteins
|
EP2672958A1
(en)
|
2011-02-08 |
2013-12-18 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
CN103930437A
(en)
|
2011-03-16 |
2014-07-16 |
安姆根有限公司 |
Potent and selective inhibitors of Nav1.3 and Nav1.7
|
EP2709669A1
(en)
|
2011-05-17 |
2014-03-26 |
Bristol-Myers Squibb Company |
Methods for maintaining pegylation of polypeptides
|
WO2012166555A1
(en)
|
2011-05-27 |
2012-12-06 |
Nektar Therapeutics |
Water - soluble polymer - linked binding moiety and drug compounds
|
US9592251B2
(en)
|
2011-06-16 |
2017-03-14 |
The Hong Kong University Of Science And Technology |
Multi-vinylsulfone containing molecule
|
JP2014518216A
(en)
|
2011-06-17 |
2014-07-28 |
ハロザイム インコーポレイテッド |
Stable formulation of hyaluronan degrading enzyme
|
EP2720713A2
(en)
|
2011-06-17 |
2014-04-23 |
Halozyme, Inc. |
Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
CA2840552A1
(en)
|
2011-07-01 |
2013-01-10 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
AU2012278944B2
(en)
|
2011-07-05 |
2015-09-17 |
Bioasis Technologies Inc. |
p97-antibody conjugates and methods of use
|
WO2013020079A2
(en)
|
2011-08-04 |
2013-02-07 |
Nektar Therapeutics |
Conjugates of an il-11 moiety and a polymer
|
US10226417B2
(en)
|
2011-09-16 |
2019-03-12 |
Peter Jarrett |
Drug delivery systems and applications
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
SG11201401797TA
(en)
|
2011-10-24 |
2014-09-26 |
Halozyme Inc |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
US9522951B2
(en)
|
2011-10-31 |
2016-12-20 |
Bristol-Myers Squibb Company |
Fibronectin binding domains with reduced immunogenicity
|
WO2013075117A2
(en)
|
2011-11-17 |
2013-05-23 |
John Wahren |
Pegylated c-peptide
|
US9205150B2
(en)
|
2011-12-05 |
2015-12-08 |
Incept, Llc |
Medical organogel processes and compositions
|
EP2858661B1
(en)
|
2011-12-29 |
2020-04-22 |
Dana-Farber Cancer Institute, Inc. |
Stabilized antiviral fusion helices
|
PT3130347T
(en)
|
2011-12-30 |
2019-12-10 |
Halozyme Inc |
Ph20 polypeptide variants, formulations and uses thereof
|
RU2659423C2
(en)
|
2012-02-16 |
2018-07-02 |
ЭйТИР ФАРМА, ИНК. |
Hystidil-trna-synthetase for treatment of autoimmune and inflammatory diseases
|
WO2013149161A1
(en)
|
2012-03-30 |
2013-10-03 |
Deangelis Paul L |
High molecular weight heparosan polymers and methods of production and use thereof
|
WO2013151991A1
(en)
|
2012-04-02 |
2013-10-10 |
Surmodics, Inc. |
Hydrophilic polymeric coatings for medical articles with visualization moiety
|
PT2833905T
(en)
|
2012-04-04 |
2018-08-06 |
Halozyme Inc |
Combination therapy with hyaluronidase and a tumor-targeted taxane
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
AU2013267161A1
(en)
|
2012-05-31 |
2014-11-20 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
AU2013270684B2
(en)
|
2012-06-08 |
2018-04-19 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US10377827B2
(en)
|
2012-06-21 |
2019-08-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind c-met
|
JP6438391B2
(en)
|
2012-06-22 |
2018-12-12 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Antigen binding protein that binds to CCR2
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
JP6433424B2
(en)
|
2012-07-31 |
2018-12-05 |
バイオアシス テクノロジーズ インコーポレイテッド |
Dephosphorylated lysosomal storage disease protein and method of use thereof
|
US9395468B2
(en)
|
2012-08-27 |
2016-07-19 |
Ocular Dynamics, Llc |
Contact lens with a hydrophilic layer
|
ES2907763T3
(en)
|
2012-08-31 |
2022-04-26 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
AU2013341711A1
(en)
|
2012-11-12 |
2015-05-21 |
Redwood Bioscience, Inc. |
Compounds and methods for producing a conjugate
|
JP2016505528A
(en)
|
2012-11-16 |
2016-02-25 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Picte-Spengler ligation for chemical modification of proteins
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
US9383357B2
(en)
|
2012-12-07 |
2016-07-05 |
Northwestern University |
Biomarker for replicative senescence
|
JP6426107B2
(en)
|
2012-12-20 |
2018-11-21 |
アムジエン・インコーポレーテツド |
APJ receptor agonists and uses thereof
|
EP2951206A2
(en)
|
2013-02-01 |
2015-12-09 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
UY35397A
(en)
|
2013-03-12 |
2014-10-31 |
Amgen Inc |
POWERFUL AND SELECTIVE INHIBITORS OF NaV1.7
|
WO2014160438A1
(en)
|
2013-03-13 |
2014-10-02 |
Bioasis Technologies Inc. |
Fragments of p97 and uses thereof
|
US10087215B2
(en)
|
2013-03-15 |
2018-10-02 |
Dana-Farber Cancer Institute, Inc. |
Stabilized SOS1 peptides
|
CA2906572A1
(en)
|
2013-03-15 |
2014-09-25 |
Dana-Farber Cancer Institute, Inc. |
Stabilized ezh2 peptides
|
EP2970417B1
(en)
|
2013-03-15 |
2019-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bh4 stabilized peptides and uses thereof
|
CN105683217B
(en)
|
2013-05-31 |
2019-12-10 |
索伦托治疗有限公司 |
Antigen binding proteins that bind to PD-1
|
TW201534726A
(en)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
Thermally stable PH20 hyaluronidase variants and uses thereof
|
ES2658039T3
(en)
|
2013-07-10 |
2018-03-08 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use
|
WO2015013510A1
(en)
|
2013-07-25 |
2015-01-29 |
Ecole Polytechnique Federale De Lausanne Epfl |
High aspect ratio nanofibril materials
|
US20150093399A1
(en)
|
2013-08-28 |
2015-04-02 |
Bioasis Technologies, Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
CN104623637A
(en)
|
2013-11-07 |
2015-05-20 |
健能隆医药技术(上海)有限公司 |
Application of IL-22 dimer in preparation of intravenous injection drugs
|
CA2930552C
(en)
|
2013-11-15 |
2022-12-13 |
Ocular Dynamics, Llc |
Contact lens with a hydrophilic layer
|
WO2015081282A1
(en)
|
2013-11-27 |
2015-06-04 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
CN112043835B
(en)
|
2013-12-06 |
2022-10-21 |
韩捷 |
Bioreversible introducing group for nitrogen and hydroxyl-containing drugs
|
CN106459210A
(en)
|
2014-03-27 |
2017-02-22 |
戴埃克斯有限公司 |
Compositions and methods for treatment of diabetic macular edema
|
MA39711A
(en)
|
2014-04-03 |
2015-10-08 |
Nektar Therapeutics |
Conjugates of an il-15 moiety and a polymer
|
JP7059003B2
(en)
|
2014-05-14 |
2022-04-25 |
トラスティーズ・オブ・ダートマス・カレッジ |
Deimmunized lysostaphin and how to use
|
JP6803236B2
(en)
|
2014-06-10 |
2020-12-23 |
アムジェン インコーポレイテッド |
Aperin polypeptide
|
DK3180018T3
(en)
|
2014-08-12 |
2019-10-28 |
Massachusetts Inst Technology |
Synergistic tumor treatment with IL-2 and integrin-binding Fc fusion protein
|
US20170216403A1
(en)
|
2014-08-12 |
2017-08-03 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
MX2017002380A
(en)
|
2014-08-22 |
2017-09-15 |
Sorrento Therapeutics Inc |
Antigen binding proteins that bind cxcr3.
|
EP3186281B1
(en)
|
2014-08-28 |
2019-04-10 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
WO2016059377A1
(en)
|
2014-10-14 |
2016-04-21 |
Polytherics Limited |
Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
|
NZ730563A
(en)
|
2014-10-14 |
2019-05-31 |
Halozyme Inc |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
EA036697B1
(en)
|
2014-10-24 |
2020-12-09 |
Бристол-Майерс Сквибб Компани |
Modified fgf-21 polypeptides and uses thereof
|
SG11201701342XA
(en)
*
|
2014-10-24 |
2017-03-30 |
Polytherics Ltd |
Conjugates and conjugating reagents
|
GB201419108D0
(en)
|
2014-10-27 |
2014-12-10 |
Glythera Ltd |
Materials and methods relating to linkers for use in antibody drug conjugates
|
CN107206119B
(en)
*
|
2014-12-09 |
2021-01-29 |
实体科学公司 |
Medical device coating with biocompatible layer
|
EP3270945A4
(en)
|
2015-03-18 |
2018-09-05 |
Massachusetts Institute of Technology |
Selective mcl-1 binding peptides
|
CN108026146A
(en)
|
2015-07-02 |
2018-05-11 |
达纳-法伯癌症研究所股份有限公司 |
Stable antimicrobial peptide
|
EP3341008A4
(en)
|
2015-08-28 |
2019-05-15 |
Dana-Farber Cancer Institute, Inc. |
Peptides binding to bfl-1
|
EA201891388A1
(en)
|
2015-12-11 |
2018-11-30 |
Дайэкс Корп. |
PLASMA KALLIKREIN INHIBITORS AND THEIR APPLICATION FOR THE TREATMENT OF THE EXPOSURE OF HEREDITARY ANGIONEUROTIC DOMESTIC
|
JP6883590B2
(en)
|
2016-01-29 |
2021-06-09 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Antigen-binding protein that binds to PD-L1
|
US20170247423A1
(en)
|
2016-02-29 |
2017-08-31 |
Dana-Farber Cancer Institute, Inc. |
Stapled intracellular-targeting antimicrobial peptides to treat infection
|
US10421785B2
(en)
|
2016-04-11 |
2019-09-24 |
Bar-Ilan University |
Delta receptor agonist peptides and use thereof
|
CN109328069B
(en)
|
2016-04-15 |
2023-09-01 |
亿一生物医药开发(上海)有限公司 |
Use of IL-22 in the treatment of necrotizing enterocolitis
|
WO2018017922A2
(en)
|
2016-07-22 |
2018-01-25 |
Massachusetts Institute Of Technology |
Selective bfl-1 peptides
|
WO2018031361A2
(en)
|
2016-08-09 |
2018-02-15 |
Eli Lilly And Company |
Combination therapy
|
US11466064B2
(en)
|
2016-08-26 |
2022-10-11 |
Dana-Farber Cancer Institute, Inc. |
Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss
|
CA3052639A1
(en)
|
2017-02-08 |
2018-08-16 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
WO2018170299A1
(en)
|
2017-03-15 |
2018-09-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inhibitors of prokaryotic gene transcription and uses thereof
|
WO2018172503A2
(en)
|
2017-03-24 |
2018-09-27 |
Basf Se |
Liquid laundry detergent comprising modified saccharide or polysaccharide
|
CN111107870A
(en)
|
2017-06-22 |
2020-05-05 |
催化剂生物科学公司 |
Modified membrane serine protease 1(MTSP-1) polypeptides and methods of use thereof
|
JP7305614B2
(en)
|
2017-07-19 |
2023-07-10 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Stabilized antimicrobial peptides for the treatment of antibiotic-resistant bacterial infections
|
EP3684811A2
(en)
|
2017-08-17 |
2020-07-29 |
Massachusetts Institute of Technology |
Multiple specificity binders of cxc chemokines and uses thereof
|
US11897917B2
(en)
|
2017-09-27 |
2024-02-13 |
The University Of York |
Bioconjugation of polypeptides
|
CN112119085A
(en)
|
2017-12-15 |
2020-12-22 |
丹娜-法伯癌症研究院有限公司 |
Stable peptide-mediated targeted protein degradation
|
JP2021506800A
(en)
|
2017-12-15 |
2021-02-22 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Structural stabilization and / or selective targeting of apoptotic proteins with cysteine-reactive NOXA peptides
|
CN111094462A
(en)
|
2017-12-26 |
2020-05-01 |
贝克顿·迪金森公司 |
Deep ultraviolet excitable water-solvated polymer dyes
|
US11952432B2
(en)
|
2018-02-07 |
2024-04-09 |
Dana-Farber Cancer Institute, Inc. |
Cell-permeable stapled peptide modules for cellular delivery
|
US20200408746A1
(en)
|
2018-03-14 |
2020-12-31 |
Dana-Farber Cancer Institute, Inc. |
Stabilized Peptides for Biomarker Detection
|
JP2021519841A
(en)
|
2018-03-30 |
2021-08-12 |
ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company |
Water-soluble polymer dye with pendant chromophore
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
KR102167755B1
(en)
|
2018-05-23 |
2020-10-19 |
주식회사 큐어바이오 |
Fragmented GRS polypeptide, mutants thereof and use thereof
|
EP3813867A1
(en)
|
2018-07-22 |
2021-05-05 |
Bioasis Technologies Inc. |
Treatment of lymmphatic metastases
|
CN111417655A
(en)
|
2018-08-28 |
2020-07-14 |
润俊(中国)有限公司 |
anti-CD3 antibody folate bioconjugates and uses thereof
|
FI3849614T3
(en)
|
2018-09-11 |
2024-02-08 |
Ambrx Inc |
Interleukin-2 polypeptide conjugates and their uses
|
EP3852783A1
(en)
|
2018-09-17 |
2021-07-28 |
Massachusetts Institute of Technology |
Peptides selective for bcl-2 family proteins
|
JP2022512746A
(en)
|
2018-10-19 |
2022-02-07 |
アンブルックス,インコーポレイテッド |
Interleukin-10 polypeptide complex, its dimer, and their use
|
US20200262887A1
(en)
|
2018-11-30 |
2020-08-20 |
Opko Ireland Global Holdings, Ltd. |
Oxyntomodulin peptide analog formulations
|
US20220075098A1
(en)
*
|
2018-12-19 |
2022-03-10 |
Tangible Science, Inc. |
Systems and methods of treating a hydrogel-coated medical device
|
KR20210110848A
(en)
|
2018-12-28 |
2021-09-09 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
Modified urokinase type plasminogen activator polypeptides and methods of use
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
WO2020154032A1
(en)
|
2019-01-23 |
2020-07-30 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
BR112021015832A2
(en)
|
2019-02-12 |
2022-01-18 |
Ambrx Inc |
Compositions containing antibody-tlr agonist conjugates, methods and uses thereof
|
EP3962933A1
(en)
|
2019-04-18 |
2022-03-09 |
Dana-Farber Cancer Institute, Inc. |
Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides
|
EP3958983A1
(en)
|
2019-04-26 |
2022-03-02 |
The Procter & Gamble Company |
Reduction of tooth staining derived from cationic antimicrobials
|
US20230116760A1
(en)
|
2019-12-16 |
2023-04-13 |
Dana-Farber Cancer Institute, Inc. |
Structurally-stabilized oncolytic peptides and uses thereof
|
EP4077366A1
(en)
|
2019-12-20 |
2022-10-26 |
Dana Farber Cancer Institute, Inc. |
Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
|
CA3166509A1
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Biased il2 muteins methods and compositions
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
JP2023517293A
(en)
|
2020-03-04 |
2023-04-25 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Antiviral structurally stabilized SARS-CoV-2 peptides and uses thereof
|
AU2021233909A1
(en)
|
2020-03-11 |
2022-09-29 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
CA3179872A1
(en)
|
2020-04-22 |
2021-10-28 |
Dana-Farber Cancer Institute, Inc. |
Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
|
US20230192789A1
(en)
|
2020-04-27 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
US20230330238A1
(en)
|
2020-10-14 |
2023-10-19 |
Dana-Farber Cancer Institute, Inc. |
Chimeric conjugates for degradation of viral and host proteins and methods of use
|
WO2022098848A1
(en)
|
2020-11-05 |
2022-05-12 |
Dana-Farber Cancer Institute, Inc. |
Antiviral structurally-stabilized ebolavirus peptides and uses thereof
|
WO2022212899A1
(en)
|
2021-04-03 |
2022-10-06 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|
IL311151A
(en)
|
2021-09-08 |
2024-04-01 |
Dana Farber Cancer Inst Inc |
Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof
|
EP4155349A1
(en)
|
2021-09-24 |
2023-03-29 |
Becton, Dickinson and Company |
Water-soluble yellow green absorbing dyes
|
WO2023215784A1
(en)
|
2022-05-04 |
2023-11-09 |
Dana-Farber Cancer Institute, Inc. |
Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof
|
WO2024007016A2
(en)
|
2022-07-01 |
2024-01-04 |
Beckman Coulter, Inc. |
Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
|
WO2024044327A1
(en)
|
2022-08-26 |
2024-02-29 |
Beckman Coulter, Inc. |
Dhnt monomers and polymer dyes with modified photophysical properties
|